Cancer: Evolution within a lifetime

Annual Review of Genetics

Volumn 48, Issue , 2014, Pages 215-236

  Gerlinger, Marco ^a,d   McGranahan, Nicholas ^a,b   Dewhurst, Sally M ^a   Burrell, Rebecca A ^a   Tomlinson, Ian ^c   Swanton, Charles ^a,e  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

cancer evolution; drug resistance; genome instability; intratumor heterogeneity; precision medicine

Indexed keywords

ARTICLE; CANCER CELL; CANCER STEM CELL; CARCINOGENESIS; CHROMOSOME REARRANGEMENT; EVOLUTION; GENE MUTATION; GENETIC HETEROGENEITY; GENOME; GENOMIC INSTABILITY; HUMAN; LIFESPAN; MUTATION RATE; NEOPLASM; NONHUMAN; TUMOR BIOPSY; CHROMOSOME ABERRATION; GENETICS; MOLECULAR EVOLUTION; MUTATION; NEOPLASMS;

CHROMOSOME ABERRATIONS; EVOLUTION, MOLECULAR; GENETIC HETEROGENEITY; HUMANS; MUTATION; NEOPLASMS;

EID: 84913590602     PISSN: 00664197     EISSN: 15452948     Source Type: Book Series    
DOI: 10.1146/annurev-genet-120213-092314     Document Type: Article

References (154)

1. Adams KL, Wendel JF. 2005. Polyploidy and genome evolution in plants. Curr. Opin. Plant Biol. 8:135-41
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, et al. 2013. Signatures of mutational processes in human cancer. Nature 500:415-21
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. 2013. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3:246-59
4. Am. Cancer Soc. 2012. Cancer Facts&Figures 2012. Atlanta, GA: Am. Cancer Soc. http://www. Cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941. pdf
5. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, et al. 2011. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469:356-61
6. Armitage P, Doll R. 1954. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 8:1-12
7. Awad MM, Engelman JA, Shaw AT. 2013. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 369:1173
8. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, et al. 2013. Punctuated evolution of prostate cancer genomes. Cell 153:666-77
9. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, et al. 2012. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44:685-89
10. Bekaert M, Edger PP, Pires JC, Conant GC. 2011. Two-phase resolution of polyploidy in the Arabidopsis metabolic network gives rise to relative and absolute dosage constraints. Plant Cell 23:1719-28
11. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, et al. 2010. Signatures of mutation and selection in the cancer genome. Nature 463:893-98
12. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, et al. 2011. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 71:3447-52
13. Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP. 1995. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat. Med. 1:902-9
14. Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3:730-37
15. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, et al. 2014. Neo-Antigens predicted by tumor genome meta-Analysis correlate with increased patient survival. Genome Res. 24:743-50
16. Burrell RA, McGranahan N, Bartek J, Swanton C. 2013. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501:338-45
17. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. 1999. Genetic instability and Darwinian selection in tumours. Trends Cell Biol. 9:M57-60
18. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, et al. 2010. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109-13
19. Cancer Genome Atlas Netw. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-15
20. Cancer Genome Atlas Netw. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-37
21. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, et al. 2012. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30:413-21
22. Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522-26
23. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, et al. 2013. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum. Mol. Genet. 22:2820-28
24. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. 2013. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45:1127-33
25. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. 2014. Tumour cell heterogeneity maintained by cooperating subclones inWnt-driven mammary cancers. Nature 508:113-18
26. Crasta K, Ganem NJ, Dagher R, Lantermann AB, Ivanova EV, et al. 2012. DNAbreaks and chromosome pulverization from errors in mitosis. Nature 482:53-58
27. Davoli T, de Lange T. 2011. The causes and consequences of polyploidy in normal development and cancer. Annu. Rev. Cell Dev. Biol. 27:585-610
28. Davoli T, Denchi EL, de Lange T. 2010. Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell 141:81-93
29. de Bruin EC, Taylor TB, Swanton C. 2013. Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Med. 5:101
30. Dewhurst SM, McGranahan N, Burrell RA, Rowan AJ, Gronroos E, et al. 2014. Tolerance of wholegenome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4:175-85
31. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, et al. 2012. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-40
32. Ding L, Ellis MJ, Li S, Larson DE, Chen K, et al. 2010. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005
33. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506-10
34. Duelli DM, Padilla-Nash HM, Berman D, Murphy KM, Ried T, Lazebnik Y. 2007. A virus causes cancer by inducing massive chromosomal instability through cell fusion. Curr. Biol. 17:431-37
35. Duesberg P, Stindl R, Hehlmann R. 2001. Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc. Natl. Acad. Sci. USA 98:11283-88
36. Duncan AW, HanlonNewell AE, Bi W, Finegold MJ, Olson SB, et al. 2012. Aneuploidy as amechanism for stress-induced liver adaptation. J. Clin. Investig. 122:3307-15
37. Duncan AW, Taylor MH, Hickey RD, Hanlon Newell AE, Lenzi ML, et al. 2010. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature 467:707-10
38. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, et al. 2012. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-60
39. Ene CI, Fine HA. 2011. Many tumors in one: a daunting therapeutic prospect. Cancer Cell 20:695-97
40. Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, et al. 1995. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 10:33-37
41. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, et al. 2010. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468:572-75
42. France D, Hebert PDN. 1994. Hybridization and origins of polyploidy. Proc. R. Soc. Lond. Ser. B 258(1352):141-46
43. Frank NY, Schatton T, Frank MH. 2010. The therapeutic promise of the cancer stem cell concept. J. Clin. Investig. 120:41-50
44. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. 2005. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437:1043-47
45. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, et al. 1996. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc. Natl. Acad. Sci. USA 93:7081-84
46. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. 2009. Adaptive therapy. Cancer Res. 69:4894-903
47. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, et al. 2014. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46:225-33
48. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883-92
49. Gerlinger M, Swanton C. 2010. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103:1139-43
50. German J. 1980. Chromosome-breakage syndromes: different genes, different treatments, different cancers. Basic Life Sci. 15:429-39
51. Gibson TC, Scheppe ML, Cox EC. 1970. Fitness of an Escherichia coli mutator gene. Science 169:686-88
52. Goldschmidt R. 1982. The Material Basis of Evolution: Reissued. New Haven, CT: Yale Univ.
53. Gorla GR, Malhi H, Gupta S. 2001. Polyploidy associated with oxidative injury attenuates proliferative potential of cells. J. Cell Sci. 114:2943-51
54. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, et al. 2012. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121-34
55. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-43
56. Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481:306-13
57. Greaves M. 2013. Cancer stem cells as "units of selection. " Evol. Appl. 6:102-8
58. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446:153-58
59. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, et al. 2013. Tracking the clonal origin of lethal prostate cancer. J. Clin. Investig. 123:4918-22
60. Hallatschek O, Nelson DR. 2010. Life at the front of an expanding population. Evolution 64:193-206
61. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, et al. 2010. Somaticmutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol. 28:3570-76
62. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, et al. 1998. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 95:6870-75
63. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-83
64. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, et al. 2012. A landscape of driver mutations in melanoma. Cell 150:251-63
65. Holland AJ, Cleveland DW. 2009. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat. Rev. Mol. Cell Biol. 10:478-87
66. Huminiecki L, Conant GC. 2012. Polyploidy and the evolution of complex traits. Int. J. Evol. Biol. 2012:292068
67. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, et al. 2006. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66:3987-91
68. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, et al. 2010. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 24:1731-45
69. Jablonski D. 2001. Lessons from the past: evolutionary impacts of mass extinctions. Proc. Natl. Acad. Sci. USA 98:5393-98
70. Jamal-Haniani M, Hackshaw A, Ngai Y, Shaw J, Dive C, et al. 2014. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLOS Biol. 12:e1001906
71. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, et al. 2014. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-93
72. Jones AM, Thirlwell C, Howarth KM, Graham T, Chambers W, et al. 2007. Analysis of copy number changes suggests chromosomal instability in a minority of large colorectal adenomas. J. Pathol. 213:249-56
73. Jonkers YM, Claessen SM, Perren A, Schmid S, Komminoth P, et al. 2005. Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr. Relat. Cancer 12:435-47
74. Kamb A, Wee S, Lengauer C. 2007. Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov. 6:115-20
75. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, et al. 2012. Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067-76
76. Kern SE. 2012. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 72:6097-101
77. Klein A, Li N, Nicholson JM, McCormack AA, Graessmann A, Duesberg P. 2010. Transgenic oncogenes induce oncogene-independent cancers with individual karyotypes and phenotypes. Cancer Genet. Cytogenet. 200:79-99
78. Korona R, Nakatsu CH, Forney LJ, Lenski RE. 1994. Evidence for multiple adaptive peaks from populations of bacteria evolving in a structured habitat. Proc. Natl. Acad. Sci. USA 91:9037-41
79. Lada AG, Dhar A, Boissy RJ, Hirano M, Rubel AA, et al. 2012. AID/APOBEC cytosine deaminase induces genome-wide kataegis. Biol. Direct 7:47
80. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-26
81. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, et al. 2014. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495-501
82. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499:214-18
83. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, et al. 1993. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-25
84. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, et al. 2011. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 71:1858-70
85. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, et al. 2012. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Investig. 122:2983-88
86. Leedham S, Tomlinson I. 2012. The continuum model of selection in human tumors: general paradigm or niche product? Cancer Res. 72:3131-34
87. Lengauer C, Kinzler KW, Vogelstein B. 1997. Genetic instability in colorectal cancers. Nature 386:623-27
88. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-49
89. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, et al. 2008. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 216:64-74
90. Liu P, Erez A, Nagamani SC, Dhar SU, Kolodziejska KE, et al. 2011. Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell 146:889-903
91. Loeb LA. 1991. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51:3075-79
92. Loh E, Salk JJ, Loeb LA. 2010. Optimization of DNA polymerase mutation rates during bacterial evolution. Proc. Natl. Acad. Sci. USA 107:1154-59
93. Lv L, Zhang T, Yi Q, Huang Y, Wang Z, et al. 2012. Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells. Cell Cycle 11:2864-75
94. Maharjan R, Seeto S, Notley-McRobb L, Ferenci T. 2006. Clonal adaptive radiation in a constant environment. Science 313:514-17
95. Maharjan RP, Ferenci T, Reeves PR, Li Y, Liu B, Wang L. 2012. The multiplicity of divergence mechanisms in a single evolving population. Genome Biol. 13:R41
96. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. 2008. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359:366-77
97. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, et al. 2006. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38:468-73
98. Martin SL, Husband BC. 2012. Whole genome duplication affects evolvability of flowering time in an autotetraploid plant. PLOS ONE 7:e44784
99. McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. 2012. Cancer chromosomal instability: therapeutic and diagnostic challenges. "Exploring aneuploidy: the significance of chromosomal imbalance" review series. EMBO Rep. 13:528-38
100. Meacham CE, Morrison SJ. 2013. Tumour heterogeneity and cancer cell plasticity. Nature 501:328-37
101. Merlo LM, Maley CC. 2010. The role of genetic diversity in cancer. J. Clin. Investig. 120:401-3
102. Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, et al. 2010. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. 3:1388-97
103. Moolgavkar SH, Knudson AG Jr. 1981. Mutation and cancer: amodel for human carcinogenesis. J. Natl. Cancer Inst. 66:1037-52
104. Muller HJ. 1964. The relation of recombination to mutational advance. Mutat. Res. 106:2-9
105. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, et al. 2011. Tumour evolution inferred by single-cell sequencing. Nature 472:90-94
106. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, et al. 2010. Inferring tumor progression from genomic heterogeneity. Genome Res. 20:68-80
107. Nguyen HG, Makitalo M, Yang D, Chinnappan D, St Hilaire C, Ravid K. 2009. Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J. 23:2741-48
108. Nikolaev SI, Sotiriou SK, Pateras IS, Santoni F, Sougioultzis S, et al. 2012. A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Res. 72:6279-89
109. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, et al. 2012. Mutational processes molding the genomes of 21 breast cancers. Cell 149:979-93
110. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, et al. 2012. The life history of 21 breast cancers. Cell 149:994-1007
111. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, et al. 2011. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469:362-67
112. Nowell PC. 1976. The clonal evolution of tumor cell populations. Science 194:23-28
113. OMIM. 2014. Online Mendelian inheritance in man. http://omim. org/
114. Otto SP, Whitton J. 2000. Polyploid incidence and evolution. Annu. Rev. Genet. 34:401-37
115. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, et al. 2013. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45:136-44
116. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, et al. 2013. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616-27
117. Rivlin N, Brosh R, Oren M, Rotter V. 2011. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2:466-74
118. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, et al. 2002. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-18
119. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, et al. 2011. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol. Biomark. Prev. 20:2183-94
120. Shackney SE, Smith CA, Miller BW, Burholt DR, Murtha K, et al. 1989. Model for the genetic evolution of human solid tumors. Cancer Res. 49:3344-54
121. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-25
122. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, et al. 2009. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461:809-13
123. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. 2012. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395-99
124. Simillion C, Vandepoele K, Van Montagu MC, Zabeau M, Van de Peer Y. 2002. The hidden duplication past of Arabidopsis thaliana. Proc. Natl. Acad. Sci. USA 99:13627-32
125. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. 2011. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810-17
126. Sottoriva A, Vermeulen L, Tavare S. 2011. Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors. PLOS Comput. Biol. 7:e1001132
127. Sprouffske K, Merlo LM, Gerrish PJ, Maley CC, Sniegowski PD. 2012. Cancer in light of experimental evolution. Curr. Biol. 22:R762-71
128. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. 2011. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27-40
129. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400-4
130. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, et al. 2012. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30:433-40
131. Swanton C. 2012. Intratumor heterogeneity: evolution through space and time. Cancer Res. 72(19):4875-82
132. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22
133. Taylor TB, Johnson LJ, Jackson RW, Brockhurst MA, Dash PR. 2013. First steps in experimental cancer evolution. Evol. Appl. 6:535-48
134. Thakur MD, Salangsang F, Landman AS, Sellers WR, Pryer NK, et al. 2013. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494(7436):251-55
135. Thirlwell C, Will OC, Domingo E, Graham TA, McDonald SA, et al. 2010. Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology 138:1441-54
136. Thompson DA, Desai MM, Murray AW. 2006. Ploidy controls the success of mutators and nature of mutations during budding yeast evolution. Curr. Biol. 16:1581-90
137. Thompson SL, Compton DA. 2011. Chromosomes and cancer cells. Chromosome Res. 19:433-44
138. Tomasetti C, Vogelstein B, Parmigiani G. 2013. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc. Natl. Acad. Sci. USA 110:1999-2004
139. Tomlinson IP, Novelli MR, Bodmer WF. 1996. The mutation rate and cancer. Proc. Natl. Acad. Sci. USA 93:1483-90
140. Trautmann K, Terdiman JP, French AJ, Roydasgupta R, Sein N, et al. 2006. Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin. Cancer Res. 12:6379-85
141. von Hansemann D. 1890. Ueber asymmetriche Zelltheilung in epithel Krebsen und deren biologische Bedeutung. Virchow's Arch. Pathol. Anat. 119:299
142. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, et al. 2012. The origin and evolution of mutations in acute myeloid leukemia. Cell 150:264-78
143. Wilson BG, Roberts CW. 2011. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11:481-92
144. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-13
145. Woodford-Richens KL, Rowan AJ, Gorman P, Halford S, Bicknell DC, et al. 2001. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc. Natl. Acad. Sci. USA 98:9719-23
146. Wu M, Pastor-Pareja JC, Xu T. 2010. Interaction between RasV12 and scribbled clones induces tumour growth and invasion. Nature 463:545-48
147. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, et al. 2012. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482:529-33
148. Xu X, Hou Y, Yin X, Bao L, Tang A, et al. 2012. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148:886-95
149. Yap T, Gerlinger M, Futreal A, Pustzai L, Swanton C. 2012. Intratumour heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 4:127ps10
150. Yates LR, Campbell PJ. 2012. Evolution of the cancer genome. Nat. Rev. Genet. 13:795-806
151. Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, et al. 2009. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J. Cell. Physiol. 219:288-300
152. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, et al. 2009. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. 15:4622-29
153. Young J, Leggett B, Gustafson C, Ward M, Searle J, et al. 1993. Genomic instability occurs in colorectal carcinomas but not in adenomas. Hum. Mutat. 2:351-54
154. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, et al. 2013. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45:1134-40